References
- Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594–8
- Hassen H J, Leonardie A, Gueeriero R, Chelucci L, Cianetti N, Ciavarella P, et al. Hemophilia “B” with inhibitor: molecular analysis of the subtotal deletion of factor IX gene. Blood 1985; 66: 728–30
- Kasper C K, Aledort L M, Counts R B, Edson J R, Fratantoni J, Green D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869–72
- Sanchez-Cuenca J M, Carmona E, Villanueva M J, Aznar JA. Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990; 57: 897–908
- Sima M, Yoshioka A, Sawamoto Y, Tanaka I, Fukiui H. Analysis of human factor VIII inhibitors using the enzyme linked immunosorbent assay (ELISA) and immunoblot technique XIIth ISTH. Kyoto Sat Symp 1990; 18–23
- Lewis R M, Reisner H M, Chung K S, Roberts HR. Detection of factor IX antibodies by radioimmunoassay: Effect of calcium on antibody-factor IX interaction. Blood 1980; 56: 608–14
- Fujimura Y, Sakai T, Matsuyama I, Mikami S, Yoshioka A, Fukui H. A simultaneous purification of human prothrombin and factor IX. Blood Vessel 1982; 13: 63–71
- Mackie I J, Seghatchian MJ. Amidolytic end-point methods for factor VIIIC inhibitors. Med Lab Sci 1982; 39: 345–50
- Astermark J, Bjork I, Ohlin A K, Stenflo J. Structural requirements for Ca2+binding to the gamma-carboxyglutamic acid and epidermal growth factor-like regions of factor IX Studies using intact domain isolated from controlled proteolytic digests of bivin factor IX. J Biol Chem 1991; 266: 2430–7
- Briet E, Reisner H M, Roberts HR. Inhibitors in Christmas disease. Prog Clin Biol Res 1984; 150: 123–39